EDGAR Filing Documents for 0001062993-18-001177

Form 40-F/A - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)]: [Amend]

SEC Accession No. 0001062993-18-001177

Filing Date

2018-03-13

Accepted

2018-03-12 18:25:27

Documents

Period of Report

2017-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 40-F/A	form40fa.htm	40-F/A	12665
2	EXHIBIT 99.3	exhibit99-3.htm	EX-99.3	434886
3	EXHIBIT 99.4	exhibit99-4.htm	EX-99.4	7118
4	EXHIBIT 99.5	exhibit99-5.htm	EX-99.5	7154
5	EXHIBIT 99.6	exhibit99-6.htm	EX-99.6	2529
6	EXHIBIT 99.7	exhibit99-7.htm	EX-99.7	2544
7	GRAPHIC	exhibit99-1x1x1.jpg	GRAPHIC	6561
	Complete submission text file	0001062993-18-001177.txt		477068

Mailing Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9

Business Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9 (416) 595-0627

Trillium Therapeutics Inc. (Filer) CIK: 0001616212 (see all company filings)